Cost-effectiveness analysis of the phase 3 IMvigor130 study evaluating atezolizumab as monotherapy or combined with platinum-based chemotherapy versus chemotherapy alone in locally advanced or metastatic urothelial cancer

• D.E. Magee,
• D.C. Cheung,
• A.E. Hird,
• S.S. Sridhar,
• N. Fallah-Rad,
• N.E. Fleshner,
• G.K. Kulkarni

Affiliations

D.E. Magee

D.C. Cheung

A.E. Hird

S.S. Sridhar

N. Fallah-Rad

N.E. Fleshner

G.K. Kulkarni